Study Goal: This study wants to see if switching to new HIV drugs, bictegravir (BIC) and lenacapavir (LEN), works as well as staying on current medicine Biktarvy (B/F/TAF). People with HIV-1 who are doing well on Biktarvy can join.

Eligibility: To join, you must have been on Biktarvy for at least 6 months and have low HIV levels in your blood. You cannot join if you are pregnant, breastfeeding, or have certain other health conditions like serious infections or liver problems.

• Study Length: The study length and number of visits will depend on how your health responds to the new drug.
• Risks: There are certain health conditions that may prevent you from joining, like liver disease or other serious infections.
• Compensation: Compensation details are not provided but may be discussed with the study team.

Note: Make sure to ask the study team any questions you have before deciding to join. They will help you understand the process and answer any concerns.